{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:23:45Z","timestamp":1790141025601,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10557-018-6838-2","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:41:03Z","timestamp":1541464863000},"page":"617-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application"],"prefix":"10.1007","volume":"32","author":[{"given":"S.","family":"Bouchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giannakoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.-P.","family":"Harjola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Karason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kivikko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"von Lewinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Parissis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-768X","authenticated-orcid":false,"given":"Piero","family":"Pollesello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"P\u00f6lzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"6838_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenpera M, Leppikangas H, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82\u20137.","journal-title":"Int J Cardiol"},{"key":"6838_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ijcard.2015.10.240","volume":"203","author":"P Pollesello","year":"2016","unstructured":"Pollesello P, Papp Z, Papp JG. Calcium sensitizers: what have we learned over the last 25 years? Int J Cardiol. 2016;203:543\u20138.","journal-title":"Int J Cardiol"},{"issue":"1","key":"6838_CR3","doi-asserted-by":"publisher","first-page":"H131","DOI":"10.1152\/ajpheart.2002.282.1.H131","volume":"282","author":"K Brixius","year":"2002","unstructured":"Brixius K, Reicke S, Schwinger RH. Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol. 2002 Jan;282(1):H131\u20137.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"6838_CR4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0009-9236(97)90139-9","volume":"61","author":"H Ukkonen","year":"1997","unstructured":"Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, N\u00e5gren K, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther. 1997;61:596\u2013607.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"6838_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/FJC.0b013e31819c9a17","volume":"53","author":"MS Nieminen","year":"2009","unstructured":"Nieminen MS, Pollesello P, Vajda G, Papp Z. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2009;53(4):302\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"6838_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/sj.bjp.0707157","volume":"150","author":"M Louhelainen","year":"2007","unstructured":"Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kyt\u00f6 V, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl\/Rapp rats. Br J Pharmacol. 2007;150(7):851\u201361.","journal-title":"Br J Pharmacol"},{"key":"6838_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","volume":"222","author":"D Farmakis","year":"2016","unstructured":"Farmakis D, Alvarez J, Gal TB, Brito D, Fedele F, Fonseca C, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303\u201312.","journal-title":"Int J Cardiol"},{"issue":"4","key":"6838_CR8","first-page":"227","volume":"5","author":"MS Nieminen","year":"2013","unstructured":"Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessels. 2013;5(4):227\u201345.","journal-title":"Heart Lung Vessels"},{"key":"6838_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijcard.2016.02.014","volume":"209","author":"P Pollesello","year":"2016","unstructured":"Pollesello P, Parissis J, Kivikko M, Harjola VP. Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol. 2016;209:77\u201383.","journal-title":"Int J Cardiol"},{"issue":"17","key":"6838_CR10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883\u201391.","journal-title":"JAMA"},{"key":"6838_CR11","first-page":"103","volume":"1","author":"M Packer","year":"2013","unstructured":"Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JCHF. 2013;1:103\u201311.","journal-title":"JCHF"},{"key":"6838_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196\u2013202.","journal-title":"Lancet"},{"issue":"18","key":"6838_CR13","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","volume":"23","author":"VS Moiseyev","year":"2002","unstructured":"Moiseyev VS, P\u00f5der P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23(18):1422\u201332.","journal-title":"Eur Heart J"},{"issue":"2","key":"6838_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00134-010-2073-4","volume":"37","author":"A Mebazaa","year":"2011","unstructured":"Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290\u2013301.","journal-title":"Intensive Care Med"},{"issue":"3","key":"6838_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijcard.2011.03.013","volume":"159","author":"MJ Bonjos","year":"2012","unstructured":"Bonjos MJ, Terrovitis JV, Drakos SG, Katsaros F, Pantsios C, Nanas SN, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol. 2012;159(3):225\u20139.","journal-title":"Int J Cardiol"},{"issue":"12","key":"6838_CR16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.amjcard.2006.07.043","volume":"98","author":"P Flevari","year":"2006","unstructured":"Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 2006;98(12):1641\u20135.","journal-title":"Am J Cardiol"},{"issue":"8","key":"6838_CR17","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1097\/CCM.0b013e3181809846","volume":"36","author":"JT Fuhrmann","year":"2008","unstructured":"Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36(8):2257\u201366.","journal-title":"Crit Care Med"},{"issue":"2","key":"6838_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/1755-5922.12001","volume":"31","author":"ZQ Hou","year":"2013","unstructured":"Hou ZQ, Sun ZX, Su CY, Tan H, Zhong X, Hu B, et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther. 2013;31(2):108\u201314.","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"6838_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/FJC.0b013e31826b86aa","volume":"60","author":"G Malfatto","year":"2012","unstructured":"Malfatto G, Della Rosa F, Villani A, Rella V, Branzi G, Facchini M, et al. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol. 2012;60(5):450\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"6838_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ejheart.2005.05.001","volume":"7","author":"D Moertl","year":"2005","unstructured":"Moertl D, Berger R, Huelsmann M, Bojic A, Pacher R. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail. 2005;7(7):1156\u201363.","journal-title":"Eur J Heart Fail"},{"key":"6838_CR21","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","volume":"102","author":"MT Slawsky","year":"2000","unstructured":"Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222\u20137.","journal-title":"Circulation"},{"key":"6838_CR22","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","volume":"36","author":"MS Nieminen","year":"2000","unstructured":"Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"6838_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/euhj.1997.0806","volume":"19","author":"J Lilleberg","year":"1998","unstructured":"Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660\u20138.","journal-title":"Eur Heart J"},{"key":"6838_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1067\/mcp.2000.110972","volume":"68","author":"H Ukkonen","year":"2000","unstructured":"Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522\u201331.","journal-title":"Clin Pharmacol Ther"},{"key":"6838_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","volume":"9","author":"J Lilleberg","year":"2007","unstructured":"Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75\u201382.","journal-title":"Eur J Heart Fail"},{"key":"6838_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/01.CIR.0000043245.00859.11","volume":"107","author":"M Kivikko","year":"2003","unstructured":"Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81\u20136.","journal-title":"Circulation"},{"key":"6838_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/eurjhf\/hfn045","volume":"11","author":"A Mebazaa","year":"2009","unstructured":"Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11:304\u201311.","journal-title":"Eur J Heart Fail"},{"key":"6838_CR28","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.jacc.2004.02.052","volume":"43","author":"S Sonntag","year":"2004","unstructured":"Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"6838_CR29","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/CIRCULATIONAHA.106.668640","volume":"115","author":"MM Givertz","year":"2007","unstructured":"Givertz MM, Andreou C, Conrad CH, Colucci WS. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation. 2007;115:1218\u201324.","journal-title":"Circulation"},{"key":"6838_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijcard.2014.04.111","volume":"174","author":"MS Nieminen","year":"2014","unstructured":"Nieminen MS, Altenberger J, Ben-Gal T, B\u00f6hmer A, Comin-Colet J, Dickstein K, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol. 2014;174:360\u20137.","journal-title":"Int J Cardiol"},{"issue":"8","key":"6838_CR31","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ejhf.118","volume":"16","author":"J Altenberger","year":"2014","unstructured":"Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16(8):898\u2013906.","journal-title":"Eur J Heart Fail"},{"key":"6838_CR32","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Com\u00edn-Colet","year":"2018","unstructured":"Com\u00edn-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garc\u00eda Pinilla JM, Almenar L, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20:1128\u201336.","journal-title":"Eur J Heart Fail"},{"key":"6838_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ijcard.2017.05.081","volume":"243","author":"G P\u00f6lzl","year":"2017","unstructured":"P\u00f6lzl G, Altenberger J, Baholli L, Beltr\u00e1n P, Borb\u00e9ly A, Comin-Colet J, et al. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. Int J Cardiol. 2017;243:389\u201395.","journal-title":"Int J Cardiol"},{"issue":"1","key":"6838_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13054-017-1849-0","volume":"21","author":"F Sanfilippo","year":"2017","unstructured":"Sanfilippo F, Knight JB, Scolletta S, Santonocito C, Pastore F, Lorini FL, et al. Levosimendan for patients with severely reduced left ventricular systolic function and\/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017;21(1):252.","journal-title":"Crit Care"},{"key":"6838_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2015.08.188","volume":"202","author":"S Silvetti","year":"2016","unstructured":"Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis. Int J Cardiol. 2016;202:138\u201343.","journal-title":"Int J Cardiol"},{"issue":"6","key":"6838_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1053\/j.jvca.2015.03.023","volume":"29","author":"B Gong","year":"2015","unstructured":"Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1415\u201325.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"6838_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijcard.2017.10.077","volume":"251","author":"A Putzu","year":"2018","unstructured":"Putzu A, Clivio S, Belletti A, Cassina T. Perioperative levosimendan in cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. Int J Cardiol. 2018;251:22\u201331.","journal-title":"Int J Cardiol"},{"issue":"2","key":"6838_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00134-014-3604-1","volume":"41","author":"G Koster","year":"2015","unstructured":"Koster G, Wetterslev J, Gluud C, Zijlstra JG, Scheeren TW, van der Horst IC, et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015;41(2):203\u201321.","journal-title":"Intensive Care Med"},{"issue":"1","key":"6838_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.jvca.2011.06.022","volume":"26","author":"A Zangrillo","year":"2012","unstructured":"Zangrillo A, Biondi-Zoccai G, Ponschab M, Greco M, Corno L, Covello RD, et al. Milrinone and mortality in adult cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2012;26(1):70\u20137.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"3","key":"6838_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","volume":"38","author":"CL Tacon","year":"2012","unstructured":"Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2012;38(3):359\u201367.","journal-title":"Intensive Care Med"},{"issue":"27","key":"6838_CR41","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"key":"6838_CR42","doi-asserted-by":"crossref","unstructured":"Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018.","DOI":"10.1002\/ejhf.1236"},{"issue":"4","key":"6838_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/ehf2.12177","volume":"4","author":"S Silvetti","year":"2017","unstructured":"Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Heart Fail. 2017;4(4):595\u2013604.","journal-title":"ESC Heart Fail"},{"key":"6838_CR44","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jchf.2016.05.001","volume":"4","author":"V Xanthakis","year":"2016","unstructured":"Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, et al. Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC Heart Fail. 2016;4:808\u201315.","journal-title":"JACC Heart Fail"},{"key":"6838_CR45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cardfail.2016.03.003","volume":"22","author":"JB Bjork","year":"2016","unstructured":"Bjork JB, Alton KK, Georgiopoulou VV, Butler J, Kalogeropoulos AP. Defining advanced heart failure: a systematic review of criteria used in clinical trials. J Card Fail. 2016;22:569\u201377.","journal-title":"J Card Fail"},{"key":"6838_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.cardfail.2015.04.013","volume":"21","author":"JC Fang","year":"2015","unstructured":"Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M, et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail. 2015;21:519\u201334.","journal-title":"J Card Fail"},{"key":"6838_CR47","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijcard.2016.05.009","volume":"218","author":"MS Nieminen","year":"2016","unstructured":"Nieminen MS, Buerke M, Cohen-Sol\u00e1l A, Costa S, \u00c9des I, Erlikh A, et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol. 2016;218:150\u20137.","journal-title":"Int J Cardiol"},{"key":"6838_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10741-007-9006-5","volume":"12","author":"HE Salzman","year":"2007","unstructured":"Salzman HE, Sharma K, Mather PJ, Rubin S, Adams S, Whellan DJ. Renal dysfunction in heart failure patients: what is the evidence? Heart Fail Rev. 2007;12:37\u201347.","journal-title":"Heart Fail Rev"},{"issue":"6","key":"6838_CR49","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S0735-1097(02)02125-3","volume":"40","author":"NG Mahon","year":"2002","unstructured":"Mahon NG, Blackstone EH, Francis GS, Starling RC 3rd, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;40(6):1106\u201313.","journal-title":"J Am Coll Cardiol"},{"key":"6838_CR50","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6838_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10557-013-6485-6","volume":"27","author":"MB Yilmaz","year":"2013","unstructured":"Yilmaz MB, Grossini E, Silva Cardoso JC, \u00c9des I, Fedele F, Pollesello P, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27(6):581\u201390.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"6838_CR52","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1476-5381.1996.tb15716.x","volume":"119","author":"PS Pagel","year":"1996","unstructured":"Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol. 1996;119(3):609\u201315.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"6838_CR53","doi-asserted-by":"publisher","first-page":"F1453","DOI":"10.1152\/ajprenal.00485.2005","volume":"290","author":"RA Zager","year":"2006","unstructured":"Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290(6):F1453\u201362.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"6838_CR54","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1097\/CCM.0b013e3181ef4694","volume":"38","author":"S Rehberg","year":"2010","unstructured":"Rehberg S, Ertmer C, Vincent JL, Spiegel HU, K\u00f6hler G, Erren M, et al. Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock. Crit Care Med. 2010;38(10):2016\u201323.","journal-title":"Crit Care Med"},{"issue":"2","key":"6838_CR55","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1124\/jpet.112.193961","volume":"342","author":"E Grossini","year":"2012","unstructured":"Grossini E, Molinari C, Pollesello P, Bellomo G, Valente G, Mary D, et al. Levosimendan protection against kidney ischemia\/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342(2):376\u201388.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"6838_CR56","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1097\/CCM.0b013e31828e946a","volume":"41","author":"G Bragadottir","year":"2013","unstructured":"Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328\u201335.","journal-title":"Crit Care Med"},{"issue":"3","key":"6838_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ejhf.9","volume":"16","author":"F Fedele","year":"2014","unstructured":"Fedele F, Bruno N, Brasolin B, Caira C, D'Ambrosi A, Mancone M. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281\u20138.","journal-title":"Eur J Heart Fail"},{"key":"6838_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008455","volume":"7","author":"L Lannemyr","year":"2018","unstructured":"Lannemyr L, Ricksten S-E, Rundqvist B, Andersson B, Bartfay S-E, Ljungman C, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double-blind controlled trial. J Am Heart Assoc. 2018;7:e008455.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"6838_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/FJC.0000000000000028","volume":"63","author":"ZZ Niu","year":"2014","unstructured":"Niu ZZ, Wu SM, Sun WY, Hou WM, Chi YF. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis. J Cardiovasc Pharmacol. 2014;63(2):107\u201312.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"6838_CR60","first-page":"35","volume":"7","author":"T Bove","year":"2015","unstructured":"Bove T, Matteazzi A, Belletti A, Paternoster G, Saleh O, Taddeo D, et al. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Heart Lung Vessel. 2015;7(1):35\u201346.","journal-title":"Heart Lung Vessel"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6838-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6838-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6838-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T19:12:41Z","timestamp":1572981161000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6838-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["6838"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6838-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"6 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"Editorial assistance in the preparation of this article was provided by Peter Hughes (Hughes associates, Oxford, UK).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing, Editorial, and Other Assistance"}},{"value":"P. Pollesello and M. Kivikko are full-time employees of Orion Pharma. The other authors report no conflicts of interest apart for the lecture honoraria related to the aforementioned educational event.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}